Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir

• Published in: Annals of hepatology Vol. 28; no. 5; p. 101119
• Main Authors: Da Wang, Fa, Zhou, Jing, Li, Lan-Qing, Li, Yu-Jing, Wang, Meng-Lan, Tao, Ya-Chao, Zhang, Dong-Mei, Wang, Yong-Hong, Chen, En-Qiang
• Format: Journal Article
• Language: English
• Published: Mexico Elsevier España, S.L.U 01.09.2023; Elsevier
• Subjects: Bone mineral density; Chronic Hepatitis B; Renal function; Tenofovir alafenamide; Tenofovir disoproxil fumarate; eGFR; NAs; Chronic Hepatitis B; Renal function; TFV; ETV; HCC; ALT; Tenofovir disoproxil fumarate; EASL; ULN; TDF; LLV; BMD; TAF; AASLD; Bone mineral density; CHB; Tenofovir alafenamide; HBV; bone mineral density; renal function; tenofovir alafenamide; tenofovir disoproxil fumarate
• ISSN: 1665-2681; 2659-5982
• DOI: 10.1016/j.aohep.2023.101119

Renal and bone impairment has been reported in chronic hepatitis B (CHB) patients receiving long-term tenofovir disoproxil fumarate (TDF) therapy. This study aimed to assess the incidence of renal and bone impairment in CHB patients with long-term TDF therapy and to identify the changes in bone mineral density (BMD) and renal function in these patients after switching to entecavir (ETV) or tenofovir alafenamide (TAF). This retrospective study collected clinical data from CHB patients who received TDF monotherapy over 96 weeks. The changes in BMD and renal function were analyzed after 96 weeks of switching antiviral regimens (ETV or TAF) or maintenance TDF. At baseline, 154 patients receiving TDF monotherapy over 96 weeks were enrolled, with a younger median age of 36.75 years, 35.1% (54/154) of patients experienced elevated urinary β2 microglobulin and 20.1% (31/154) of patients had reduced hip BMD(T<-1). At week 96, among the 123 patients with baseline normal BMD, patients who maintained TDF (n=85) had experienced a decrease in hip BMD, while patients who switched antiviral regimens (n=38) experienced an increase (-13.97%vs2.34%, p<0.05). Among patients with a baseline reduced BMD (n=31), the alterations in BMD were similar in patients who maintained TDF (n=5) and those who switched antiviral regimens (n=26)(-15.81%vs7.35%, p<0.05). Irrespective of baseline BMD status, renal function decreased significantly in patients who maintained TDF and improved in patients who switched antiviral regimens. Younger CHB patients on long-term TDF therapy are at high risk for bone and renal impairment, with the risk being reduced when switched to ETV or TAF.